Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $8.7 million.

  • Lisata Therapeutics' Shares Outstanding (Weighted Average) rose 501.14% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 501.14%. This contributed to the annual value of $8.3 million for FY2024, which is 317.11% up from last year.
  • Lisata Therapeutics' Shares Outstanding (Weighted Average) amounted to $8.7 million in Q3 2025, which was up 501.14% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, Lisata Therapeutics' Shares Outstanding (Weighted Average) peaked at $8.7 million during Q3 2025, and registered a low of $8.0 million during Q1 2023.
  • In the last 3 years, Lisata Therapeutics' Shares Outstanding (Weighted Average) had a median value of $8.3 million in 2024 and averaged $8.3 million.
  • In the last 5 years, Lisata Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 221.1% in 2024 and then surged by 501.14% in 2025.
  • Over the past 3 years, Lisata Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $8.1 million in 2023, then grew by 3.17% to $8.3 million in 2024, then increased by 4.91% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $8.6 million for Q2 2025, and $8.6 million during Q1 2025.